Payment overview · 2025
General Payments
$216.79
12 reported records · 8 companies
Healthcare provider profile · identity verified
Carrie Ellen Valle, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COOS BAY, OR · NPI 1508589607
Verified facts
What the public records show
CMS Open Payments records show Carrie Ellen Valle, FNP-C received $216.79 in general payments during 2025 across 12 reported records.
Exact Sciences Corporation accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.48 | 21.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.77 | 15.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.24 | 14.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.94 | 14.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.07 | 9.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.08 | 8.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.79 | 8.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.42 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.79 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
125 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 69 |
| Losartan Potassium | Losartan Potassium | 211 | 78 |
| Gabapentin | Gabapentin | 203 | 62 |
| Lisinopril | Lisinopril | 186 | 66 |
| Omeprazole | Omeprazole | 184 | 61 |
| Metformin Hcl | Metformin Hcl | 177 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 40 |
| Furosemide | Furosemide | 136 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 43 |
| Eliquis | Apixaban | 125 | 32 |
| Potassium Chloride | Potassium Chloride | 119 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 36 |
| Ozempic | Semaglutide | 81 | 15 |
| Tramadol Hcl | Tramadol Hcl | 78 | 36 |
| Alendronate Sodium | Alendronate Sodium | 71 | 22 |
| Carvedilol | Carvedilol | 64 | 25 |
| Simvastatin | Simvastatin | 64 | 24 |
| Allopurinol | Allopurinol | 63 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 23 |
| Methocarbamol | Methocarbamol | 61 | 19 |
| Trazodone Hcl | Trazodone Hcl | 61 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 18 |
| Jardiance | Empagliflozin | 58 | 16 |
| Prednisone | Prednisone | 57 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 27 |
| Lorazepam | Lorazepam | 56 | 15 |
| Warfarin Sodium | Warfarin Sodium | 55 | 20 |
| Metformin Hcl Er | Metformin Hcl | 53 | 14 |
| Celecoxib | Celecoxib | 52 | 19 |
| Montelukast Sodium | Montelukast Sodium | 52 | 20 |
| Sertraline Hcl | Sertraline Hcl | 51 | 17 |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 12 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Famotidine | Famotidine | 41 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Meloxicam | Meloxicam | 39 | 13 |
| Spironolactone | Spironolactone | 39 | 12 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Pregabalin | Pregabalin | 36 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 13 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Baclofen | Baclofen | 27 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Valsartan | Valsartan | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.79 · 12 records | Exact Sciences Corporation | FARXIGA, GEMTESA, LEQVIO, NURTEC ODT, REXULTI, The Cologuard Plus Collection Kit, Veozah, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error